Sec Form 13G Filing - 6 Dimensions Capital L.P. filing for Viela Bio Inc. (VIE) - 2020-02-05

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No.     )*

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13G

(1)         Percentage calculated based on 50,962,060 shares of common stock, being the common stock outstanding as of November 14, 2019, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 14, 2019.

2

SCHEDULE 13G

(1)         Percentage calculated based on 50,962,060 shares of common stock, being the common stock outstanding as of November 14, 2019, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 14, 2019.

3

SCHEDULE 13G

(1)         Percentage calculated based on 50,962,060 shares of common stock, being the common stock outstanding as of November 14, 2019, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 14, 2019.

4

SCHEDULE 13G

(1)         Percentage calculated based on 50,962,060 shares of common stock, being the common stock outstanding as of November 14, 2019, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 14, 2019.

5

Item 1(a) Name of Issuer:

Viela Bio, Inc.

Item 1(b) Address of Issuer’s Principal Executive Offices:

One MedImmune Way, First Floor, Area Two, Gaithersburg, Maryland 20878.

Item 2(a) Name of Person Filing:

This Schedule 13G is filed jointly by the following persons (each a “Reporting Person” and collectively, the “Reporting Persons”):

1.              6 Dimensions Capital, L.P. (“6D Capital”);

2.              6 Dimensions Affiliates Fund, L.P. (“6D Fund”);

3.              6 Dimensions Capital GP, LLC (“6D GP”); and

4.              Dr. Lianyong Chen (“Dr. Chen”).

Item 2(b) Address of Principal Business Office or, if None, Residence:

The address of the principal business office of each of the Reporting Persons is Unit 6706, 67/F, The Center, 99 Queen’s Road Central, Central, Hong Kong.

Item 2(c) Citizenship or Place of Organization:

The place of organization of each of 6D Capital, 6D Fund and 6D GP is the Cayman Islands. The citizenship of Dr. Chen is the United States.

Item 2(d) Title of Class of Securities:

Common stock, par value $0.001 per share (the “Common Stock”).

Item 2(e) CUSIP Number:

926613100

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

Not applicable.

Item 4. Ownership.

(a)         Amount Beneficially Owned:

(i)    6D Capital directly owns 4,124,118 shares of Issuer’s Common Stock. 6D GP is the general partner of 6D Capital. Dr. Chen is the largest shareholder of 6D GP and controls 6D GP. Each of 6D GP and Dr. Chen may be deemed to beneficially own the shares held by 6D Capital.

(ii)   6D Fund directly owns 217,059 shares of Issuer’s Common Stock. 6D GP is the general partner of 6D Fund. Dr. Chen is the largest shareholder of 6D GP and controls 6D GP. Each of 6D GP and Dr. Chen may be deemed to beneficially own the shares of Common Stock held by 6D Fund.

(b)         Percent of Class:

See Row 11 of the cover page for each Reporting Person.

6

(c)          Number of shares as to which such persons have:

(i)             Sole power to vote or to direct the vote: See Row 5 of the cover page for each Reporting Person.

(ii)          Shared power to vote or to direct the vote: See Row 6 of the cover page for each Reporting Person.

(iii)       Sole power to dispose or to direct the disposition of: See Row 7 of the cover page for each Reporting Person.

(iv)      Shared power to dispose or to direct the disposition of: See Row 8 of the cover page for each Reporting Person.

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

Not applicable.

7

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 5, 2020

8

EXHIBIT INDEX

9